Mahindra Holidays gains after Q1 PAT jumps 34% YoY to Rs 8 cr
Revenue from operations rose 7.43% YoY to Rs 701.40 crore for the quarter ended 30 June 2025.
Profit before tax (PBT) stood at Rs 26.29 crore in Q1 FY26, marking an 87.25% increase from Rs 14.04 crore reported in the same quarter last year.
During the quarter, EBITDA grew 16.3% YoY to Rs 161.2 crore, while the EBITDA margin improved to 21.8%, up from 20.2% reported in Q1 FY25.
Manoj Bhat, Managing Director and Chief Executive Officer, Mahindra Holidays & Resorts India, said, "We have delivered a strong performance this quarter. Our domestic business continues to do very well. Our standalone profit grew by 69% and our PAT margin expanded by 680 bps. Resort performance has been consistent with double-digit revenue growth and sustained occupancy of 85%+ on an expanded inventory base. We have commenced a new expansion project and are focused on achieving our aspiration of 10,000 rooms by FY30. Our strategy of selective member addition while pursuing premiumization is reflected in continued growth in average unit sales realization.
Our European operation, HCRO, has improved its performance in a weak seasonal quarter, showing resilience amidst multiple economic headwinds. Our consolidated profits were impacted by adverse currency movements largely due to the sharp movement in the Euro. Despite this, our consolidated profits up by 18% YoY."
Mahindra Holidays & Resorts India, India's leading company in the leisure hospitality industry, offers quality family holidays primarily through vacation ownership memberships. While Club Mahindra is the flagship brand, the other brands offered by the company are Club Mahindra Fundays and Svaastha Spa.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
23 minutes ago
- First Post
US, EU strike trade deal with broad 15% tariff on most European goods
The US and the EU have finalised a framework trade agreement, introducing a sweeping 15% US tariff on most European imports. read more European Commission President Ursula von der Leyen sits with U.S. President Donald Trump, after the announcement of a trade deal between the U.S. and EU, in Turnberry, Scotland, Britain. Reuters The United States struck a framework trade deal with the European Union on Sunday, imposing a 15% U.S. import tariff on most EU goods, but averting a spiralling battle between two allies which account for almost a third of global trade. The announcement came after European Commission President Ursula von der Leyen travelled for talks with U.S. President Donald Trump at his golf course in western Scotland to push a hard-fought deal over the line. STORY CONTINUES BELOW THIS AD
Economic Times
23 minutes ago
- Economic Times
U.S. EU trade deal: Donald Trump slaps 15 per cent tariffs on European goods, auto. What is new in it? Is China next?
US-Europe Trade Deal US-EU Tariffs Live Events USA-China Trade Deal Nearing? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US President Donald Trump and EU chief Ursula von der Leyen Sunday announced they had reached a deal to end a transatlantic tariffs standoff and avert a full-blown trade war. The agreement came as the clock ticked down on an August 1 deadline for the European Union to strike a deal with Washington -- or face an across-the-board US levy of 30 percent. Trump told reporters the deal involved a baseline levy of 15 percent on EU exports to the United States -- the same level secured by Japan -- including for the bloc's crucial auto sector, which is currently being taxed at 25 percent. Now all eyes are on the world's second largest economy - US President also said the bloc had agreed to purchase "$750 billion worth of energy" from the United States, as well as $600 billion more in additional investments in the country. Negotiating on behalf of the EU's 27 countries, von der Leyen's European Commission had been pushing hard to salvage a trading relationship worth an annual $1.9 trillion in goods and EU has been hit by multiple waves of tariffs since Trump reclaimed the White House. It is currently subject to a 25-percent levy on cars, 50 percent on steel and aluminium, and an across-the-board tariff of 10 percent, which Washington threatens to hike to 30 percent in a no-deal 15 percent would be much higher than pre-existing US tariffs on European goods, which average around 4.8 percent, it would mirror the status quo, with companies currently facing an additional flat rate of 10 the talks failed, EU states had greenlit counter tariffs on $109 billion (93 billion euros) of US goods including aircraft and cars to take effect in stages from August 7. Brussels was also drawing up a list of US services to potentially has embarked on a campaign to reshape US trade with the world, and has vowed to hit dozens of countries with punitive tariffs if they do not reach a pact with Washington by August 1. US Commerce Secretary Howard Lutnick had said Sunday the August 1 deadline was firm and there will be "no extensions, no more grace periods".U.S. President Donald Trump said on Sunday his administration was close to reaching a trade deal with China, but gave no other details. "We're very close to a deal with China. We really sort of made a deal with China, but we'll see how that goes," Trump told reporters at the start of a meeting with European Commission President Ursula von der Leyen in Scotland.A1. While 15 percent would be much higher than pre-existing US tariffs on European goods, which average around 4.8 percent, it would mirror the status quo, with companies currently facing an additional flat rate of 10 percent.A2. US President Donald Trump also said the bloc had agreed to purchase "$750 billion worth of energy" from the United States, as well as $600 billion more in additional investments in the country.
Economic Times
23 minutes ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
